Biogen stock holds near $209 after Q2 beat
Published on 08/18/2026 at 19:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Biogen Inc. (US09062X1037) stock traded at $209.15 on August 17, 2026, after the company reported second-quarter 2026 adjusted EPS of $3.60 and revenue of $2.74 billion. The shares also sat close to a 52-week range of $131.52 to $219.72, with a market cap of $30.90 billion as of August 17, 2026.
Q2 showed a clear beat
The latest quarter landed above expectations: EPS of $3.60 topped the $2.94 consensus by $0.66, while revenue of $2.74 billion exceeded the $2.46 billion forecast. Revenue rose 3.4% from the same quarter a year earlier, and FY 2026 guidance remained at $12.00 to $13.00 per share.
Analysts stay constructive
Market data compiled on August 18, 2026 showed a consensus rating of Moderate Buy and an average price target of $227.07, versus a close of $209.15 on August 17, 2026. That leaves the market focusing on execution in the second half of 2026 after a quarter that also showed a 11.18% return on equity and an 8.32% net margin.
Trading activity was still active, with 617,104 shares changing hands in the latest session against an average volume of 981,864 shares. The stock has gained 18.8% from its 2026 starting level of $175.99.
What Biogen sells
Biogen's neuroscience portfolio remains anchored by products for multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. That mix still matters for revenue visibility because the business combines legacy medicines with newer launches and partner programs.
Shares and valuation
Biogen stock closed at $209.15 on August 17, 2026, with an extended-hours indication of $209.44 at 7:47 a.m. Eastern on August 18, 2026. The shares traded at 37.02 times trailing earnings and 6.48 times PEG, a valuation that keeps earnings delivery in sharp view.
Fact box
Company: Biogen Inc.
ISIN: US09062X1037
Ticker: BIIB
Exchange: NASDAQ
Price (as of August 17, 2026, 4:00 p.m. ET): $209.15 USD
Market cap: $30.90 billion (as of August 17, 2026)
Sector / Industry: Healthcare / Biotechnology
Index membership: Nasdaq-100
More on Biogen stock
Biogen's commercial story still runs through its approved therapies and the revenue they contribute across neurology. The company's guidance and quarterly beat keep the next phase tied to operating discipline rather than headline growth alone.
